[Multiple sclerosis: cost of the illness].

Area of Science:

• Health Economics
• Neurology
• Public Health

Background:

• Economic assessments for multiple sclerosis (MS) emerged in the 1990s, initially with minor drug costs before interferon-beta introduction.
• MS, a chronic illness, presents varying disability levels, necessitating indirect cost analyses.
• Previous economic studies focused on cost-of-illness, but a comprehensive analysis considering methodology, healthcare systems, and disability was needed.

Purpose of the Study:

• To evaluate the economic burden of multiple sclerosis (MS).
• To analyze cost-of-illness studies for MS.
• To present findings based on methodology, healthcare system, and patient disability levels.

Main Methods:

• Systematic review of cost-of-illness studies for MS.
• Database interrogation of Medline from 1985 to 2001.
• Analysis categorized by methodology, healthcare system, and patient disability.

Main Results:

• Indirect costs of MS are associated with patient age at symptom onset, typically between 20-40 years.
• Hospital costs represent the dominant direct cost component in most countries, with the exception of the United Kingdom.
• The overall economic cost of MS is significantly influenced by the stage of the disease.

Conclusions:

• The economic impact of MS is multifaceted, influenced by patient demographics, healthcare utilization, and disease progression.
• Understanding these cost drivers is crucial for resource allocation and healthcare policy development in MS management.
• Future economic assessments should continue to integrate direct and indirect costs across different healthcare systems and disease severities.